Figure 5. .

Effect of bevacizumab on inflammatory angiogenic sprouting. (A) Photomicrographs of bevacizumab- or IgG-treated corneas of BALB/c mice on day 3 after IL-1β implantation. (B) Double staining of corneal flat mounts for angiogenic endothelium (CD31, green) and perfused blood vessels (ConA, red) in IL-1β–implanted corneas of bevacizumab- or IgG-treated mice on day 3. Arrows, angiogenic sprouts. Bar, 50 μm. (C) Quantitation of the number of angiogenic tips/angiogenic loops on day 3 with IgG or bevacizumab treatment from day 2 (n = 6–7). **P < 0.01.